logo-loader
viewe-Therapeutics PLC

e-Therapeutics PLC using its drug discovery platform in search for COVID-19 antivirals

e-therapeutics PLC's (LON:ETX) CTO Jonny Wray talks Proactive London's Andrew Scott through their drug discovery platform, the work they've done to date and what they're doing currently to help find effective antivirals against coronavirus.

The firm's computer simulation platform has successfully found active compounds capable of protecting human cells in influenza and Wray believes a similar approach could be used to identify combinations of compounds in the fight against the virus which causes Covid-19.

Quick facts: e-Therapeutics PLC

Price: 21.75 GBX

AIM:ETX
Market: AIM
Market Cap: £70.13 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of e-Therapeutics PLC named herein, including the promotion by the Company of e-Therapeutics PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

e-Therapeutics begins experimental testing on first set of compounds for...

e-Therapeutics PLC's (LON:ETX) chief scientific officer Alan Whitmore speaks to Proactive London's Andrew Scott after announcing they've begun experimental testing on the first set of compounds for the treatment of coronavirus (COVID-19) identified using its proprietary network-driven drug...

1 week, 5 days ago

2 min read